Briacell Therapeutics shares rise 2.40% after-hours after receiving a $2.05 million grant for prostate cancer immunotherapy.

Briacell Therapeutics Corp. rose 2.40% in after-hours trading, following the announcement of a $2,054,651 non-dilutive grant from the US National Cancer Institute (NCI) to advance Bria-PROS+, its next-generation personalized off-the-shelf immunotherapy for prostate cancer. The grant will support the manufacturing of Bria-PROS+ clinical supply and the upcoming Phase 1/2a trial in patients with metastatic prostate cancer.